HOUSTON, TEXAS, May 04, 2026
Cellenkos has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its lead candidate CK0802, enabling the initiation of a Phase 1b/2a clinical trial in patients with steroid-refractory graft-versus-host disease (GVHD). This milestone marks a critical advancement for a first-in-class, off-the-shelf regulatory T cell (Treg) therapy designed to address a severe and life-threatening complication of allogeneic stem cell transplantation. The multicenter, open-label study will evaluate the safety, tolerability, and preliminary efficacy of CK0802, with trial initiation expected in the second half of 2026 and initial data anticipated in early 2027.
IND Clearance Advances First-in-Class Treg Therapy Development
The FDA’s IND clearance underscores confidence in Cellenkos’ preclinical, clinical, and manufacturing data package, validating its proprietary CRANE® platform for Treg cell therapy production. CK0802 is designed as a cryopreserved, ready-to-use therapy derived from cord blood, offering a significant advantage over traditional cell therapies that require patient-specific customization and complex logistics.
This “off-the-shelf” capability enables rapid administration, which is critical in steroid-refractory GVHD, where disease progression can be rapid and fatal. The Phase 1b/2a study will enroll patients who have failed to respond to standard corticosteroid treatment, with the primary endpoint focused on overall response rate at Day 29, a key measure of early therapeutic benefit.
Novel Mechanism Targets Immune Dysregulation at Its Source
Advertisement
CK0802 leverages regulatory T cells (Tregs) to restore immune balance by addressing the root cause of GVHD—uncontrolled donor T-cell activity and cytokine-driven inflammation. Unlike conventional therapies that broadly suppress the immune system, CK0802 employs a multi-modal mechanism of action, including the release of anti-inflammatory cytokines such as IL-10, consumption of IL-2 to deprive pathogenic T cells of survival signals, and direct neutralization of antigen-presenting cells (APCs) that drive disease progression.
Additionally, CK0802 promotes infectious tolerance, retraining the patient’s immune system to maintain long-term immune homeostasis. This targeted approach has the potential to reduce systemic toxicity while delivering durable therapeutic effects, addressing a major limitation of existing GVHD treatments.
Addressing High Unmet Need in GVHD Treatment Landscape
GVHD remains one of the most serious complications following allogeneic hematopoietic stem cell transplantation, affecting up to 50% of transplant recipients, with steroid-refractory cases associated with poor prognosis and survival rates near 30% at two years. Current second-line therapies often fail to provide sustained benefit and are associated with significant immunosuppression and toxicity, highlighting the urgent need for innovative, targeted therapies.
From a GxP perspective, the CK0802 clinical program adheres to Good Clinical Practice (GCP) and regulatory standards, ensuring data integrity, patient safety, and compliance throughout development. The therapy’s long shelf life of up to three years and immediate availability further enhance its potential for scalable clinical use and rapid deployment in critical care settings.
By advancing CK0802 into clinical trials, Cellenkos is positioning itself at the forefront of next-generation immunotherapy and regenerative medicine, leveraging cell-based precision therapeutics to address complex inflammatory diseases. The successful development of CK0802 could represent a paradigm shift in GVHD treatment, offering a safer, more effective alternative to traditional immunosuppressive therapies and significantly improving outcomes for patients facing this devastating condition. As the field of cell therapy continues to evolve, innovations like CK0802 highlight the growing importance of targeted immune modulation and personalized medicine in transforming the future of healthcare.
Source: Cellenkos press release
